Watch at 2 PM today for a gift!
On December 16, 2024, local time, Novo Nordisk issued another announcement, stating that it plans to invest8.5 billion Danish kroner(approximately 1.2 billion US dollars)InOdense, Denmark(Danish: Odense)Establish brand-new production facilities.According to a press release from Novo Nordisk, this marks the first time Novo Nordisk has broken ground on a construction project in Denmark this century. Additionally, this follows the recent approval by the European Commission of Novo Holdings' acquisition of Catalent and Novo Nordisk's purchase of three manufacturing plants from Novo Holdings, representing another significant step by Novo Nordisk to enhance its production capacity.
Image Source: Novo Nordisk Official Website
According to the information disclosed by Novo Nordisk, the new factory set up in Denmark is expected to be completed and put into use by 2027, with a total area of over 40,000 square meters, and is estimated to create 400 permanent jobs.As for the use of the new factory, Novo Nordisk pointed out that it will mainly be used to supportProducing Rare Disease Products, such as hemophilia, etc.The rare disease sector is indeed a key focus for Novo Nordisk in the coming period. According to Novo Nordisk's Q3 2024 financial report, the company’s work in 2025 will mainly focus on four disease areas: first, its most proficient area, diabetes; second, the currently highly watched area of obesity; third, rare diseases; and fourth, cardiovascular diseases.
Image Source: Novo Nordisk Official WebsiteNovo Nordisk's current layout in the rare disease field is mainly distributed in hemoglobinopathies.(Haemoglobinopathies, can be divided into abnormal hemoglobin diseases and thalassemia), Rare Bleeding Disorders(Rare Bleeding Disorders, including coagulation factor deficiencies and platelet dysfunction, etc.)And growth disorders, etc. In the past period, Novo Nordisk has developed and successfully obtained approval for many products in these disease areas.(See the figure below). Among them, NovoSeven®and Norditropin®Accounted for over 60% of Novo Nordisk's rare disease segment revenue in the past period.
Image Source: Novo Nordisk Official WebsiteAccording to the information on Novo Nordisk's official website, it currently has three rare disease projects in Phase III clinical trials or above.1. Concizumab(An anti-TFPI antibody)This product has been developed for the prophylactic treatment of Hemophilia A and B. It has already been approved for marketing in Japan, Australia, and Switzerland, and received positive feedback from the EMA about a month ago. However, the FDA has not yet approved this product for market; in fact, in May 2023, the FDA issued a Complete Response Letter (CRL) to Novo Nordisk regarding the application for this product.Second, Mim8. Public data shows that the clinical trial for hemophilia A of this product has entered Phase III clinical stage, with plans to submit relevant applications to regulatory authorities by the end of this year. In addition to the two products mentioned above, Novo Nordisk has anotherOral Small Molecule Product for the Treatment of Sickle Cell DiseaseEntered Phase III clinical stage.Currently,Novo NordiskRevenue in the rare disease sector is steadily increasing. As for post-2025, Novo Nordisk has indicated that it will continue to develop within the rare disease field and expand into more disease areas.1. Novo Nordisk Official Website2.Other Public InformationCover image source: pixabay
Copyright Statement/Disclaimer
This article is an original article.
This article is for information exchange purposes only and does not provide any commercial, medical, or investment advice.
The images, videos, fonts, music, and other materials in the article are either authorized genuine works purchased by Yaotimes, sourced from the WeChat public image library, taken from the company's official website or the internet. Some materials are used under the CC0 protocol, and their copyrights belong to the respective owners. Yaotimes makes every effort to credit the sources.
If you have any questions, please contact us.
Sincerely grateful!
DrugTimes Official Website: www.drugtimes.cn
Contact Information:
Phone: 13651980212
WeChat: 27674131
Email: contact@drugtimes.cn
Click to view more highlights!
